NurExone Biologic Inc. closes private placement financing

1 minute read
05 January 2024

On January 5, 2024, NurExone Biologic Inc. (formerly, EnerSpar Corp.) ("NurExone") (TSXV: NRX) announced that it closed a private placement financing through the issuance of 7,091,993 units of the company for gross proceeds of $1,985,758.04.

NurExone is a pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.

Gowling WLG advised NurExone with respect to this private placement with a team that included Jason A. Saltzman, Andrew Avis and student-at-law Derek Varrin.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.